Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 19/20 | 1.00 |
| ▸ | PLA2G1B | P04054 | 8/20 | 1.00 |
| ▸ | PLA2G10 | O15496 | 5/20 | 1.00 |
| ▸ | PLA2G5 | P39877 | 4/20 | 1.00 |
| ▸ | PLA2G2E | Q9NZK7 | 4/20 | 1.00 |
| ▸ | PLA2G2F | Q9BZM2 | 2/20 | 0.77 |
| ▸ | PLA2G2D | Q9UNK4 | 2/20 | 0.77 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.77 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.77 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 0.77 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 0.77 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694834 | 0.99 | PLA2G2A (0.98) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL6694841 | 0.99 | PLA2G2A (0.98) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL818631 | 0.95 | PLA2G2A (1.00) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL14531294 | 0.94 | PLA2G2A (0.88) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL819886 | 0.93 | PLA2G2A (1.00) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL2156611 | 0.93 | PLA2G2A (1.00) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL4653536 | 0.92 | PLA2G2A (0.85) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL5533842 | 0.91 | PLA2G2A (0.84) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL818556 | 0.91 | PLA2G2A (0.83) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL6694837 | 0.91 | PLA2G2A (0.83) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2154958-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | Anthera Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | claimed |
| US-20090062369-A1 | USE OF SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS TO DECREASE SPLA2 LEVELS | ANTHERA PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | claimed |
| WO-2008137803-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | claimed |
| EP-1157704-B1 | SPLA2 INHIBITORS FOR THE TREATMENT OF ISCHAEMIC REPERFUSION INJURY | SHIONOGI & CO (JP) | 2006-06-14 | — | — | EP | claimed |
| EP-1084108-A4 | SPLA 2? INHIBITOR COMPOUNDS FOR TREATMENT OF DISEASE | LILLY CO ELI (US) | 2005-01-12 | — | — | EP | claimed |
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | LOH ANDREW (US) | 2004-06-10 | — | — | US | claimed |
| US-6610728-B2 | SPLA2 inhibitor, secretory phospholiase A2 inhibitors 1H-indole-3-glyoxylamide compound or a pharmaceutically acceptable salt, solvate, or a prodrug | ELI LILLY AND COMPANY | 2003-08-26 | — | — | US | claimed |
| US-20030149000-A1 | Method for the treatment of disorders associated with apoptosis using N-heterocyclic glyoxylamide compounds | SHIONOGI & CO., LTD. | 2003-08-07 | — | — | US | claimed |
| US-20030119860-A1 | METHOD FOR TRATMENT OF NON-RHEUMATOID ARTHRITIS | ELI LILLY AND COMPANY | 2003-06-26 | — | — | US | claimed |
| US-20030092767-A1 | Combination therapy for the treatment of inflammatory and respiratory diseases | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | claimed |
| US-5919943-A | INHIBITION OF SPLA2 | ELI LILLY AND COMPANY (US) | 1999-07-06 | — | — | US | claimed |
| WO-1999025339-A1 | TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1999-05-27 | — | — | WO | claimed |
| WO-1999024033-A1 | METHOD FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH APOPTOSIS USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 1999-05-20 | — | — | WO | claimed |
| WO-1999024026-A2 | METHOD FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH APOPTOSIS USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 1999-05-20 | — | — | WO | claimed |
| WO-1999016453-A1 | METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS | ELI LILLY AND COMPANY (US) | 1999-04-08 | — | — | WO | claimed |
| WO-1998047508-A1 | METHOD FOR THE TREATMENT OF STROKE USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 1998-10-29 | — | — | WO | claimed |
| WO-1998047507-A1 | METHOD FOR THE TREATMENT OF STROKE USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 1998-10-29 | — | — | WO | claimed |
| WO-1998042343-A1 | METHOD FOR TREATMENT OF CHRONIC BRONCHITIS | ELI LILLY AND COMPANY (US) | 1998-10-01 | — | — | WO | claimed |
| US-5654326-A | SEPTIC SHOCK; HUMAN NONPANCREATIC SECRETORY PHOSPHOLIPASE | ELI LILLY AND COMPANY (US) | 1997-08-05 | — | — | US | claimed |
| EP-0675110-A1 | 1H-Indole-3-glyoxylamide sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1995-10-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | PLA2G12A, PLA2G2E, PLA2G3 | PLA2G2A 24/4885PLA2G1B 9/4885PLA2G10 10/4885 |
| US-20030149000-A1 | Method for the treatment of disorders associated with apoptosis using N-heterocyclic glyoxylamide compounds | BAX, CASP3, CASP5 | PLA2G2A 3271/4885PLA2G1B 2849/4885PLA2G10 3491/4885 |
| US-20030092767-A1 | Combination therapy for the treatment of inflammatory and respiratory diseases | SERPINB1, ELANE, SPINT2 | PLA2G2A 127/4885PLA2G1B 74/4885PLA2G10 97/4885 |
| US-20090062369-A1 | USE OF SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS TO DECREASE SPLA2 LEVELS | PLA2G12A, PLA2G3, PLA2G2E | PLA2G2A 15/4885PLA2G1B 5/4885PLA2G10 10/4885 |
| US-20030119860-A1 | METHOD FOR TRATMENT OF NON-RHEUMATOID ARTHRITIS | TPP2, PLAAT2, PLAA | PLA2G2A 139/4885PLA2G1B 59/4885PLA2G10 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.